10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Santen Pharmaceutical Co's 10-Year ROIIC % for the quarter that ended in Mar. 2023 was -13.04%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Santen Pharmaceutical Co's 10-Year ROIIC % or its related term are showing as below:
SNPHY's 10-Year ROIIC % is ranked worse than 74.65% of 986
companies
in the Drug Manufacturers industry
Industry Median: 3.53
vs SNPHY: -13.04
Santen Pharmaceutical Co 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Santen Pharmaceutical Co's 10-Year ROIIC %
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co's 10-Year ROIIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's 10-Year ROIIC % falls into.
Santen Pharmaceutical Co 10-Year ROIIC % Calculation
Santen Pharmaceutical Co's 10-Year ROIIC % for the quarter that ended in Mar. 2023 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Santen Pharmaceutical Co (OTCPK:SNPHY) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Santen Pharmaceutical Co 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Santen Pharmaceutical Co's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.
Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNPHY has been successfully added to your 